Cargando…
Management of therapeutic unfractionated heparin in COVID‐19 patients: A retrospective cohort study
BACKGROUND: Patients hospitalized with severe acute respiratory syndrome coronavirus 2 infection are at risk for thrombotic complications necessitating use of therapeutic unfractionated heparin (UFH). Full‐dose anticoagulation limits requirements for organ support interventions in moderately ill pat...
Autores principales: | Weeks, Lachelle D., Sylvester, Katelyn W., Connors, Jean M., Connell, Nathan T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114028/ https://www.ncbi.nlm.nih.gov/pubmed/34013153 http://dx.doi.org/10.1002/rth2.12521 |
Ejemplares similares
-
Evaluation of Antifactor-Xa Heparin Assay and Activated Partial
Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated
Heparin Therapy
por: McLaughlin, Kevin, et al.
Publicado: (2019) -
Time in the Therapeutic Range for Assessing Anticoagulation Quality in
Patients Receiving Continuous Unfractionated Heparin
por: Ting, Clara, et al.
Publicado: (2018) -
Derivation and Validation of Age- and Body Mass Index-Adjusted Weight-Based
Unfractionated Heparin Dosing
por: Schurr, James W., et al.
Publicado: (2019) -
Impact of COVID-19 on monitoring of therapeutic unfractionated heparin
por: Adie, Sarah K., et al.
Publicado: (2020) -
Resistance to unfractionated heparin in the ICU: evaluation and management options
por: Levy, Jerrold H., et al.
Publicado: (2023)